Unia Europejska -
fiński -
EMA (European Medicines Agency)
incruse ellipta (previously incruse)
glaxosmithkline (ireland) limited - umeklidiniumbromidia - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - osoitettu hoidon bronkodilataattorikäsittelyksi oireiden lievittämiseksi aikuispotilailla, joilla on krooninen obstruktiivinen keuhkosairaus (copd).
Unia Europejska -
fiński -
EMA (European Medicines Agency)
rolufta ellipta (previously rolufta)
glaxosmithkline trading services limited - umeklidiniumbromidia - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - rolufta on merkitty hoito-bronkodilataattorikäsittelyksi oireiden lievittämiseksi aikuispotilailla, joilla on krooninen obstruktiivinen keuhkosairaus (copd).
Unia Europejska -
fiński -
EMA (European Medicines Agency)
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
Unia Europejska -
fiński -
EMA (European Medicines Agency)
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - kaikki muut terapeuttiset tuotteet - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
Unia Europejska -
fiński -
EMA (European Medicines Agency)
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomidi - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
Unia Europejska -
fiński -
EMA (European Medicines Agency)
teriflunomide accord
accord healthcare s.l.u. - teriflunomidi - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit, selektiiviset immunosuppressantit - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
